Emergent BioSolutions | EBS - Кредиторская задолженность





Кредиторская задолженность Изменить Дата
Acadia Pharmaceuticals USD 12.25M 1.34M 2026-03
Akebia Therapeutics USD 8.39M 12.8M 2026-03
ALKERMES USD 142.86M 40.5M 2026-06
Alnylam Pharmaceuticals USD 108.02M 18.61M 2026-06
Amarin USD 18.8M 29.36M 2026-06
ANI Pharmaceuticals USD 69.69M 7.11M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Coherus Biosciences USD 9.91M 14.98M 2025-12
Emergent BioSolutions USD 112.2M 500K 2023-12
Exelixis USD 24.15M 5.47M 2026-03
Glaxosmithkline GBP 14.34B 6.39B 2026-03
Heron Therapeutics USD 8.97M 24K 2026-03
Ionis Pharmaceuticals USD 47.7M 21.67M 2026-06
Ironwood Pharmaceuticals USD 3.24M 339K 2026-03
Lexicon Pharmaceuticals USD 3M 87K 2026-03
Lonza CHF 471M 3M 2024-12
Merck USD 3.86B 541M 2026-03
Moderna USD 167M 6M 2026-06
Myriad Genetics USD 30.4M 2.2M 2026-06
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Pacira USD 14.01M 1.14M 2026-03
Pfizer USD 4.51B 734M 2026-03
PTC Therapeutics USD 40.45M 14.96M 2026-06
Sanofi EUR 23.6B 888M 2026-06
Sarepta Therapeutics USD 70.38M 210.46M 2026-03
United Therapeutics USD 498.3M 491.2M 2026-03
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12